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ABSTRACT 
Objective: A simple, precise, and accurate stability indicating high-performance thin layer chromatography method was developed and validated of 
vildagliptin (VIL) and metformin (MET) in pharmaceutical dosage forms. 
Methods: In the present study, system suitability test, stress study, alkali hydrolysis, acid hydrolysis, neutral hydrolysis, oxidative stress degradation, 
dry heat degradation, wet heat degradation, photodegradation study has been used. In this method, optimization by changing various parameters, such 
as organic solvent and the composition of the mobile phase, acid or base modifier used in the mobile phase; by varying one parameter and keeping all 
other conditions constant. 10 µl of the stock solution for MET (500 ng/band) and 2 µl of the stock solution for VIL (100 ng/band) were applied to TLC 
plates. The final solutions were applied on the HPTLC plates and these were developed as per the optimized densitometry conditions. 
Results: From the spectra, it was observed that MET and VIL exhibited good absorbance at about 217 nm. Both the drugs showed degradation with 
additional peaks at Rf values of 0.16 for MET and with Rf values 0.81 for VIL respectively. The method was validated for linearity, precision, accuracy, 
limit of detection, limit of quantification, ruggedness, specificity, and robustness. Good separation was achieved by using the mobile phase Hexane: 
Methanol: Acetonitrile: Glacial Acetic Acid (2:3.5:2.5:0.2 v/v/v/v) with retardation factor (Rf) values of 0.22±0.01 for MET and 0.73±0.02 for VIL. 
Conclusion: A validated HPTLC method was developed for the determination of metformin hydrochloride and vildagliptin. The method is simple, 
quick, and can be applied routinely for the analysis of these drugs from marketed dosage forms. 
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Metformin (MET) is known for its anti-diabetic properties, which is 
chemically, 1,1-dimethyl biguanide hydrochloride [1]. The important 
properties include; high efficacy, safety profile, beneficial 
cardiovascular and metabolic effects and therapeutic benefit in 
association with other antidiabetic drugs. Therefore metformin is 
included in first-line therapy to treat patients with type II diabetes 
mellitus [2]. In the present study, complimentary actions have 
drawn in focus to the usage of metal ong with a newer class of anti-
diabetic drugs, VIL the dipeptidyl peptidase (DPP)-4 inhibitors [1]. 
The literature survey reveals that several analytical methods are 
reported for quantitative estimation of metformin alone in body 
fluids and in pharmaceutical formulations. Those methods include 
spectrophotometry, electrochemical methods, HPLC, liquid 
chromatography-electrospray ionization tandem mass spectrometry 
and electrophoresis [3]. Reverse phase high performance liquid 
chromatographic method (RP-HPLC) for simultaneous estimation of 
metformin is also reported [4]. Studies have shown that age, gender, 
and body mass index (BMI) have no clinically relevant effects on the 
pharmacokinetics or pharmacodynamics of vildagliptin [5, 6] till 
time there is no noted HPTLC method for the estimation for 
vildagliptin and metformin hydrochloride combination in the 
pharmaceutical dosage forms. A synchronized improvement in β-cell 
function was also observed in subjects who had higher baseline 
HbA1C levels showed a greater response to metformin and 
vildagliptin treated patients [7, 8]. The present study was aimed to 
develop and validation stability indicating HPTLC method for 
determination of vildagliptin and metformin hydrochloride in the 
pharmaceutical dosage forms. 
MATERIALS AND METHODS 
Pure vildagliptin and metformin hydrochloride were procured from 
Matrix Pharma, Nashik, India as a gift sample. Acetonitrile, methanol, 
and water were all of HPLC grade procured from Merck Ltd., 
Mumbai, India. Potassium dihydrogen phosphate, hydrochloric acid, 
sodium hydroxide, anhydrous sodium acetate, glacial acetic acid, 
orthophosphoric acid were purchased from Priya scientifics, Vapi, 
India, were of analytical reagent grade.  
Preparation of solutions  
Stock standard solution VIL and MET was prepared by dissolving 7.5 
mg VIL and 300 MET in methanol in a 50 ml volumetric flask. 
Working standard solution of VIL and MET was prepared at a 
concentration of 15 ng µl-1 and 600 ng µl-1 respectively, by diluting 
the stock standard solution in methanol. The stock solution was 
stored at 2-8 ° C protected from light.  
Instrumentation 
The samples were spotted in the form of bands 6 mm width with 
a Camag 100 microlitre sample syringe (Hamilton, Bonaduz, 
Switzerland) on silica gel precoated aluminum plate 60 F254, 
[(20 × 10 cm) with 250 µm thickness; E. Merck, Darmstadt, 
Germany, supplied by Anchrom Technologists, Mumbai] using a 
Camag Linomat IV applicator (Switzerland). The plates were 
prewashed with methanol and activated at 110 ° C for 5 min 
prior to chromatography. A constant application rate of 0.1 µls-1 
was used and the space between two bands was 6 mm. The slit 
dimension was kept at 5 mm × 0.45 mm and the scanning speed 
was 10 mm s-1. Linear ascending development was carried out 
in 20 cm × 10 cm twin trough glass chamber (Camag, Muttenz, 
Switzerland) saturated with the mobile phase. The optimized 
chamber saturation time for mobile phase was 30 min at room 
temperature (25±2 ° C). The length of chromatogram run was 8 
cm. Densitometric scanning was performed using a Camag TLC 
scanner III in the reflectance-absorbance mode and operated by 
CATS software (V 3.15, Camag). The sources of radiation used 
were deuterium and tungsten lamp with a spectral range from 
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190 to 800 nm. Concentrations of the compound 
chromatographed were determined from the intensity of the 
diffused light. The evaluation was by peak areas with linear 
regression.  
Selection of Analytical Wavelength A UV spectrum for the solution of 
VIL was recorded in a 10 mm cell over the range 200-400 nm using 
methanol in the reference cell. Isotretinoin showed maximum 
absorbance at 340 nm while MET was detected at 410 nm.  
Optimization of mobile phase 
In an attempt to optimize the mobile phase, methanol-ethyl acetate-
toluene–glacial acetic acid mixtures in different proportions were 
investigated. It was also observed that chamber saturation time and 
solvent migration distance were crucial in the chromatographic 
separation process; the chamber saturation time of less than 30 min and 
solvent migration distances greater than 80 mm resulted in the diffusion 
of the analyte band. The mobile phases used are shown in table 1. 
 
Table 1: Optimization of mobile phase 
Mobile phase composition with their proportion Result 
methanol: toluene: ammonia (9: 1: 0.5, v/v/v) Very High Rf value is not considerable and peak shape is broad 
methanol: toluene: glacial acetic acid (8: 2: 0.5, v/v/v) Very High Rf value is not considerable 
methanol: toluene: glacial acetic acid (5: 5: 0.5, v/v/v) Very low Rf values obtained that were not considerable and peak shape is not sharp 
hexane: methanol: acetonitrile: glacial acetic acid (2.5: 3.5:3: 
0.1, v/v/v) 
Rf values were considerable but VIL Rf value is more than 0.8 
Peak shape of MET, VIL is improved 
hexane: methanol: acetonitrile: glacial acetic acid (2: 3.5: 
2.5:0.2 v/v/v/v). 
MET and VIL were well resolved with peak purity of MET-0.998 and VIL-0.997 with 
a sharp peak of MET and VIL. 
VIL: vildagliptin; MET: metformin; v/v: volume by volume 
 
The ratio of glacial acetic acid in the mobile phase had an effect 
mainly on the shape of the VIL and MET. Good separation was 
achieved by using the mobile phase hexane: methanol: 
acetonitrile: glacial acetic acid (2:3.5:2.5:0.2 v/v/v/v) with 
retardation factor (Rf) values of 0.22±0.01 for MET and 0.73±0.02 
for VIL. The Rf values of MET and VIL was confirmed separately by 
applying on the TLC plate same concentration and same 
densitometry condition shown in fig. 1. For a selection of 
analytical wavelength for quantification of drugs, the standard 
spots were applied on silica gel and were scanned between 200-
400 nm and spectra obtained. From the spectra, it was observed 
that MET and VIL exhibited good absorbance at about 217 nm, 




Fig. 1: Typical densitogram of metformin hydrochloride (MET=0.22) and vildagliptin (VIL=0.73) standard in mixture solution 
 
RESULTS AND DISCUSSION 
The method was validated for linearity, precision, accuracy, limit 
of detection, limit of quantification, ruggedness. The International 
Conference on Harmonisation (ICH), US Food and Drug 
Administration (USFDA). US Pharmacopeia (USP) has published 
guidelines for method validation for analytical methods for 
pharmaceutical products. The most common validation 
parameters have been briefly described [9-15]. 
System suitability 
The system suitability parameters like Rf values, peak purity peak 
areas of VIL and MET were calculated.  
System suitability tests were carried out on freshly prepared 
standard stock solutions of 200ng/band for MET and 50ng/ 
band for VIL and parameters obtained are summarized in table 
2. 
Stress study 
The stress studies were carried out under the conditions of 
hydrolysis, photolysis, oxidation and dry heat, as defined in the ICH 
guideline Q1A (R2).  
These stock solutions of VIL and MET were used for forced 
degradation studies. The summary of stress study is shown in 
table 3. 
 
Table 2: System suitability test parameters 
System suitability parameter  (MET)  (VIL) 
Peak Purity 0.998 0.997 
Rf value 0.22±0.01 0.73±0.02 
Peak Area 7082.74±36.63 1673.3±9.53 
VIL: vildagliptin; MET: metformin 
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Table 3: Forced degradation studies data of vildagliptin and metformin hydrochloride by the developed HPTLC method 
Stress condition Time  (MET)  (VIL) 
% assay % degrade % assay % degrade 
Alkaline hydrolysis (1N NaOH) 60 min 82.80 17.20 90.85 9.15 
Acidic hydrolysis (1N HCl) 60 min 93.43 6.57 93.52 6.48 
Neutral hydrolysis(distill Water) 120 min 93.64 6.36 94.15 5.85 
Oxidative degradation (3% H2O2) 240 min 97.46 2.54 96.56 3.44 
Dry heat(80 °C) 240 min 96.34 3.66 94.54 5.46 
Wet heat (Boiling water bath) 240 min 98.53 1.47 97.52 2.48 
Sun light 72 hr 98.15 1.85 91.25 8.75 
UV radiation (254 nm) 240 min 98.13 1.87 98.09 1.91 
UV radiation(365 nm) 240 min 97.85 2.15 96.67 3.33 
VIL: vildagliptin; MET: metformin 
 




The base-treated stress degradation densitogram of VIL and MET in 
the mixture is as shown in fig. 2. Both the drugs showed degradation 
with additional peaks at Rf values of 0.16 for MET and with Rf values 
0.81 for VIL respectively. MET was found to be 17.20% degraded in 
alkali medium while VIL was 9.15% degraded.  
The peaks of the degradation products of both drugs were well 
resolved from the VIL and MET drug peaks [16-18]. 
 
 
Fig. 2: Typical densitogram of vildagliptin and metformin hydrochloride and its degradation products in the alkali medium 
 
Acid hydrolysis 
The acid treated stress degradation densitogram of VIL and MET in 
the mixture is shown in fig. 3 and were found to undergo acid 
hydrolysis. Additional peaks at Rf values of 0.16 respectively and 
0.77 were observed for MET and VIL respectively. MET was found to 
be 6.57% degraded in acid medium whereas VIL was 6.48% 
degraded. The peaks of the degradation products of VIL and MET 
were well resolved from the VIL and MET drug peaks. 
Neutral hydrolysis 
Neutral hydrolysis study showed that VIL and MET were stable 
under neutral conditions. The neutral hydrolysis chromatograms of 
MET and VIL were as shown in fig. 4. There was no additional peak 
observed. 
Oxidation-induced degradation study 
The oxidative stress degradation densitogram of MET and VIL in 
the mixture was as shown in fig. 5. The drugs were found to 
undergo slight oxidative degradation. Additional peaks at Rf values 
of 0.16 and 0.75, 0.77 were observed for MET and VIL respectively. 
MET was found to be 2.54% degraded while VIL was 3.44% 
degraded under oxidative conditions.  
The peaks of the degradation products of MET and VIL were well 
resolved from the MET and VIL peaks. 
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Fig. 3: Typical densitogram of vildagliptin and metformin hydrochloride and its degradation products in the acid medium 
 
 
Fig. 4: Typical densitogram of vildagliptin and metformin hydrochloride and its degradation products in the neutral medium 
 
 
Fig. 5: Typical densitogram of vildagliptin and metformin hydrochloride and its degradation products in the oxidative medium 
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Thermal degradation (wet heat and dry heat) studies 
For dry heat degradation study solution of VIL and MET was stress 
at dry heated at 80 °C for 240 min in the oven. In the dry heat 
degradation study, it was found that MET and VIL were labile and 
additional peaks emerged at Rf values of 0.32 and 0.83 for MET and 
VIL. MET was found to be 3.66% degraded and VIL was found to be 
5.46% degraded. The peaks of the degradation products were well 
resolved from the drug peaks.  
The wet heat stress degradation densitogram of MET and VIL in the 
mixture is shown in fig. 6 and it was found that MET and VIL were 
liable to wet heat degradation. Additional peaks at Rf values of 0.32 
(fig. 6) and 0.83 (fig. 6) for MET and VIL. MET was found to be 1.47% 
degraded whereas VIL was found to be 2.48% degraded. The peaks 
of the degradation products of MET and VIL were well resolved from 
the drug peaks. 
Photodegradation study 
Photodegradation of VIL and MET indicated they were quite 
stable in sunlight fig. 7. MET was found to be 1.85% degraded 




Fig. 6: Typical densitogram of vildagliptin and metformin hydrochloride and its degradation products after wet heat stress condition 
 
 
Fig. 7: Typical densitogram of vildagliptin and metformin hydrochloride and its degradation products after sunlight stress condition 
 
 
Fig. 8: Typical densitogram of vildagliptin and metformin hydrochloride and its degradation products after UV light (254 nm) stress 
condition 
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Furthermore, a stress degradation study in direct UV radiation was 
performed by exposing the solid drugs of MET and VIL and their 
mixture to UV radiation at 254 and 365 nm. The UV light 
degradation (254 nm and 365 nm) chromatograms of MET and VIL 
are shown in fig. 8. MET was found to be 1.87% degraded VIL was 
found to be 1.91% degraded in UV light (254 nm) stress conditions. 
MET was found to be 2.15% degraded VIL to be 3.33% degraded in 
UV light (365 nm) stress conditions. In photodegradation study and 
UV light degradation study of MET and VIL, no additional peak in 
HPLC chromatograms was found only decrease in the peak areas of 
MET and VIL was observed. 
Linearity and range (calibration curve for vildagliptin and 
metformin hydrochloride) 
The calibration curves were obtained by plotting the peak area versus 
concentration over the range of 50-500 ng/band for MET and 10-150 
ng/band for VIL, respectively in mix standard. The calibration curve 
data of MET and VIL was shown in table 4 and table 5. 
  
Table 4: Result of calibration curve for MET 
Concentration (ng/band) Peak area meana±SD % RSD 
50 1786.24±64.74 1.16 
100 3652.55±50.84 0.82 
200 7082.62±74.24 1.47 
300 10341.52±83.88 1.23 
400 14542.28±96.69 1.17 
500 17823.70±160.62 1.55 
RSD: relative standard deviation; SD: standard deviation 
 
Table 5: Result of calibration curve for VIL 
Concentration (ng/band) Peak area meana±SD % RSD 
10 338.31±64.74 1.61 
20 735.51±50.84 1.23 
50 1678.26±74.24 1.73 
100 3321.25±83.88 1.31 
125 4355.81±96.69 1.77 
150 5124.09±160.62 1.85 
a = Average of three determinant \ SD =Standard deviation. % RSD = Percentage relative  
 
Standard deviation 
The regression equation was found to be y = 35.73x-27.35 and 
correlation coefficient of 0.998 for MET. The regression equation 
was found to be y = 34.16x+1.352 with a correlation coefficient of 
0.999 for VIL. Each response was the average of three 
determinations. The statistical analysis data of calibration curve 
intercept, slope, and regression equation are shown in table 6. 
  
Table 6: Statistical analysis data of calibration curve 
Parameters MET VIL 
Linear range 50-500 ng/band 10-150 ng/band 
Slope 35.73 34.16 
Intercept 27.35 1.35 
Regression coefficient (r2) 0.998 0.999 
Standard deviation of slope 0.179 0.826 
Standard deviation of intercept 1.501 1.041 
LOD (ng/band) 8.2 1.74 
LOQ (ng/band) 27.06 5.74 
LOD = Limit of detection, LOQ = Limit of quantitation; VIL: vildagliptin; MET: metformin 
 
Precision 
The repeatability of developed method was determined by 
analyzing 200 ng/band MET solution and 50 ng/band VIL solution 
six times on the same day. The percentage RSD was found to be 1.5 
for both the drugs. The results of the intermediate precision 
(Intraday precision and Interday precision) experiments are 
shown in table 7 for MET. 
  
Table 7: Repeatability study 
Concentration  (MET)  (VIL) 






Mean 7232.833 1601.000 
SD 108.754 27.878 
% RSD 1.5 1.7 
VIL: vildagliptin; MET: metformin; RSD: relative standard deviation; SD: standard deviation 
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Replicate analyses of three different concentrations 50, 200 and 400 
ng/band of MET solutions showed good reproducibility. The 
percentages RSD of intraday and interday studies were found to be 
0.9–1.3% and 1.20-1.80% respectively for MET. 
Replicate analyses of three different concentrations 10, 50 and 150 
ng/band of VIL solution showed good reproducibility and the 
percentage RSD of intraday and interday studies were found to be 
0.80–1.70% and 1.20–1.80% respectively for VIL. 
Thus the developed method was found to be precise and repeatable 
on the basis of the mean CV values for the repeatability and 
intermediate precision studies which were<2 for VIL and MET 
respectively. The separations of the drug and various degradation 
products in a mixture of stressed samples were found to be similar 
when the analyses were performed with an LC system on different 
days. 
Reproducibility of the developed method was determined by two 
different analysts under the same chromatographic condition and on 
same liquid chromatography instrument for the 200 ng/band for 
MET and 50 ng/band for VIL concentration level respectively. The 
effect on the peak was evaluated by applying the F-test. There was 
no significant difference was found indicating that the developed 
method was reproducible. The reproducible results are shown in 
table 8 and 9 for MET and VIL respectively. 
 
Table 8: Intraday and inter-day precision study for MET 
Intraday precision 
Conc. (ng/band) (Area±SD) (n=3) %RSD 
50 1794.67±25.01 1.40 
200 7019.67±64.07 0.90 
500 17815.33±303.27 1.70 
Interday precision 
50 1746.00±28.35 1.60 
200 7059.33±86.82 1.20 
500 17888.67±330.61 1.80 
n=Three determination; RSD: relative standard deviation; SD: standard deviation 
 
Table 9: Intraday and inter-day precision study for VIL 
Intraday precision 
Conc. (ng/band) (Area±SD) (n=3) %RSD 
10 344.66±4.16 1.20 
50 1590.00±27.07 1.70 
150 5185.67±39.55 0.80 
Interday precision 
10 360.34±5.51 1.50 
50 1612.00±29.10 1.80 
150 5219.67±61.45 1.20 
n=Three determination; RSD: relative standard deviation; SD: standard deviation 
 
Accuracy 
The recovery of the method was carried out by the standard 
addition to the pre-analysed test sample at three different 
concentration levels 80%, 100%, and 120%. Triplicate 
determinations were made at each concentration level. Known 
amounts of standards of MET (0, 160, 200 and 240 ng per band) and 
VIL (0, 40, 50 and 60 ng per band) were spiked to a pre-quantified 
sample 200ng/band for MET and 50 ng/band for VIL and the 
mixtures were analyzed by proposed HPTLC method.  
The percentage recovery of VIL and MET was determined by 
measuring the peak areas and fitting these values into the regression 
equation of the calibration plot. The recoveries were found to be 
98.84-102.50 % for MET and 99.08–103.60 % for VIL, respectively. 
The values indicate that the method is accurate (table 10). 
 
Table 10: Accuracy study 
Level Drug added (ng/band) Drug recovered (ng/band)a % Drug recovered ±SD 
Metformin hyrdochloride 
80 160 158.15 98.84±1.98 
100 200 201.31 100.65±1.51 
120 240 246.02 102.50±1.41 
Vildagliptin 
80 40 41.44 103.60±1.05 
100 50 51.25 102.50±1.24 
120 60 59.45 99.08±0.83 
a=Average of three determination; SD: standard deviation 
 
Limit of detection and limit of quantitation 
The detection limits for MET and VIL were found to be 8.2 
ng/band and 1.74 ng/band, respectively, while quantitation limits 
were found to be 27.06 ng/band and 5.74 ng/band, respectively. 
This data indicates that a microgram quantity of both the drugs 
can be accurately and precisely determined. The values of LOD and 
LOQ of VIL and MET respectively indicate the sensitivity of the 
proposed method. 
Specificity and selectivity 
The peak purity index and HPTLC chromatogram showed peaks for 
both the drugs without any interfering peak and the estimation of both 
the drugs were found to be satisfactory. The test solution was 
prepared by mixing of VIL and MET with the tablet powder excipients. 
The peak purity of both drugs was assessed by comparing the 
respective spectra of standard drugs and samples at peak start, peak 
apex and peak end positions of the spot shown in fig. 9. 
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Fig. 9: Purity spectra of vildagliptin and metformin hydrochloride 
 
Specificity is proven by comparing the chromatogram of diluent, 
standard solution, and test solution and by peak purity index to 
show that there was no any interference of excipients with the peak 
of VIL and MET (fig. 10). 
 
 
Fig. 10: Typical densitogram of vildagliptin and metformin hydrochloride in mix standard 
 
The appearance of VIL and MET spots at specific Rf different from its 
degradation products indicated the specificity of the proposed 
method. 
Robustness 
The robustness of the method was evaluated by assessing the 
effect of variations in method parameters on peak areas of VIL and 
MET. The optimized densitometry conditions of mobile phase 
were hexane: methanol: acetonitrile: glacial acetic acid 
(2:3.5:2.5:0.2 v/v/v/v), chamber saturation time is 30 min, solvent 
migration distance is 80 mm and detection wavelength is 245 nm. 
The small changes chamber saturation time is 25 min and 35 min, 
and solvent migration distance is 70 mm and 90 mm, and mobile 
phase composition was hexane: methanol: acetonitrile: glacial 
acetic acid (2.5:3.5:2:0.2 v/v/v/v and 2.5:3:2.5:0.2 v/v/v/v, 
2:3:3:0.2 v/v/v/v) and the small changes in detection wavelength 
240 nm and 250 nm were evaluated. After small changes in this 
parameter effect on the peak area of VIL and MET was determined. 
The low values of RSD indicated that the proposed method was 
robust, as small but deliberate changes in method parameters had 
no detrimental effect on the method performance as shown in 
table 11. The low value of % RSD indicated that the method is 
robust. 
Solution stability 
The solution stability study revealed that VIL and MET solutions 
were stable for 48 h without detectable degradation. The percentage 
amount of both the drugs was found to be satisfactory (table 12). 
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Table 11: Robustness study for MET and VIL 
Parameters MET (200ng/band) VIL (50ng/band) 
% RSD % RSD 
Changed proportion of mobile phase 2.5:3.5:2:0.2 1.39 2.19 
2.5:3:2.5:0.2 1.48 1.23 
2:3:3:0.2 1.05 1.71 
Proportion of mobile phase used 2:3.5:2.5:0.2 1.07 0.39 
Changed 
migration distance 
70 mm 1.25 1.88 
90 mm 1.40 1.60 
Migration distance used 80 mm 0.70 0.89 
Changed chamber 
saturation time 
25 min 1.22 1.68 
35 min 1.49 1.56 
Saturation time used 30 min 0.78 0.08 
Detection wavelength 240 nm 1.28 1.31 
250 nm 1.05 1.41 
Detection wavelength 245 nm 0.74 0.39 
VIL: vildagliptin; MET: metformin; RSD: relative standard deviation 
 
Table 12: Solution stability study 
Time Area of METa Area of GLIb % amount drug found (n=3) 
Area of MET Area of GLI 
0 h. 7382 1678 100.48 99.98 
4.0 h. 7123 1655 99.19 98.51 
8.0 h. 6854 1650 99.16 98.21 
24.0 h. 6988 1644 98.00 97.85 
48.0 h. 7034 1642 97.78 97.73 
a200ng/band for MET, b50ng/band for GLI 
 
 
Fig. 11: Typical densitogram of MET and VIL in marketed formulation 
 
The summary of method validation parameter and their result are 
shown in table 13 indicates that the developed method is validated 
as per ICH guidelines and result are within the ICH guidelines 
values.
 
Table 13: Summary of validation parameters 
Parameters MET VIL 
Linear range 50-500 ng/band 10-150 ng/band 
Regression coefficient 0.998 0.999 
Regression equation y = 35.73x-27.35 y = 34.16x+1.352 













Limit of Detection(ng/spot) 8.2 1.74 
Limit of quantitation (ng/spot) 27.06 5.74 
Robustness Robust Robust 
Solvent stability Stable for 48 h Stable for 48 h 
Specificity Specific Specific 
Peak purity 0.998 0.998 
VIL: vildagliptin; MET: metformin; RSD: relative standard deviation 
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Analysis of marketed formulations 
The developed HPTLC method was successfully applied for the 
estimation of VIL and MET in the marketed dosage form. The 
marketed formulation, JALRA M 50/500 Tab and GALVUS M 50/500 
Tab were analyzed using the developed HPTLC method. The 
chromatogram of tablet sample showed that at Rf values of 0.22 and 
0.73 for MET and VIL respectively, indicating that there was no 
interference of the excipients present in the tablet formulation.  
The content of VIL and MET was calculated by comparing peak areas 
of samples with that of the standard. The marketed formulation was 
analyzed using proposed method which gave percentage recovery of 
more than 97.0 for VIL and MET (table 14). 
  
Table 14: Assay results of marketed formulation 
Formulation Drug Amount taken (mg) Amount foundn (mg) % MET ± SD %VIL ± SD 
JALRA M Tab MET 500 505.55 101.11±1.87 99.00±1.18 
VIL 50 48.65 
GALVUS M Tab MET 500 490.55 98.11±1.72 98.54±1.21 
VIL 50 51.45 
VIL: vildagliptin; MET: metformin; SD: standard deviation 
 
CONCLUSION 
A validated HPTLC method was developed for the determination of 
metformin hydrochloride and vildagliptin. The developed method is 
simple, quick, and can be applied routinely for the analysis of these 
drugs from marketed dosage forms. The proposed method was found 
to be simple, precise, accurate, rapid and specific for determination of 
vildagliptin and metformin from pure and its dosage forms. The 
mobile phase is simple to prepare and economical. The sample 
recoveries in the formulation were in good agreement with their 
respective label claims and they suggested non-interference of 
formulation excipients in the estimation. Hence, this method can be 
easily and conveniently adopted for routine analysis of vildagliptin and 
metformin in pure form and its dosage form. 
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